The following is a summary of "Clinicopathologic and genomic analyses of SMARCA4-mutated non-small cell lung carcinoma ...

Findings from a phase 2 trial published in JTO Clinical and Research Reports suggest that pembrolizumab (Keytruda) plus ...

During a live event, Alexander I. Spira, MD, PhD, and participants discuss efficacy, adverse events, and sequencing of ...

Lung cancer remains one of the leading causes of cancer-related mortality, with lung adenocarcinoma (LUAD) and lung squamous cell carcinoma (LUSC) representing the most prevalent subtypes of non-small ...

For nearly 20 years, mesothelioma treatment options were limited to a single regimen: pemetrexed with a platinum agent. Now, ...

Nasopharyngeal Cancer Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.

Suggested remit: To appraise the clinical and cost effectiveness of cemiplimab with chemotherapy within its marketing authorisation for untreated advanced or metastatic NSCLC.

A lifesaving medication has been urgently recalled and demanded to be under quarantine by the UK government due to results found during testing ...